AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 23(4), 1974, pp. 565-569
Copyright © 1974 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, L. H.
Right arrow Articles by Neva, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, L. H.
Right arrow Articles by Neva, F. A.

Evaluation of Clindamycin in Combination with Quinine against Multidrug-Resistant Strains of Plasmodium Falciparum

Louis H. Miller, Richard H. Glew*, David J. Wyler, William A. Howard{dagger}, William E. Collins, Peter G. Contacos{ddagger} AND Franklin A. Neva
Malaria Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014

The efficacy of clindamycin, a slow acting antimalarial, in combination with a rapid acting schizonticidal drug, quinine, was determined against three multidrug-resistant strains of Plasmodium falciparum (Cambodian I, Burma [Thau] and Panama II). No recrudescences occurred after treatment with quinine 650 mg orally every 8 hours for 3 days and clindamycin 450 mg orally every 6 hours for 3 days, when administered either simultaneously or sequentially. Quinine alone for 3 days was not curative against infections with these strains. During a 3-day course of therapy, blood levels of quinine or clindamycin were not influenced by administration of the other drug.

Accepted for publication December 29, 1973.


* Massachusetts General Hospital, Boston, Massachusetts 02114.


{dagger} Mayo Clinic, Rochester, Minnesota 55901.


{ddagger} Center for Disease Control, Atlanta, Georgia 30333.




This article has been cited by other articles:


Home page
JAMAHome page
K. S. Griffith, L. S. Lewis, S. Mali, and M. E. Parise
Treatment of Malaria in the United States: A Systematic Review
JAMA, May 23, 2007; 297(20): 2264 - 2277.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
B. Lell and P. G. Kremsner
Clindamycin as an Antimalarial Drug: Review of Clinical Trials
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2315 - 2320.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. J. Wyler
Fluoroquinolones for Malaria: The Newest Kid on the Block?
Ann Intern Med, August 15, 1989; 111(4): 269 - 271.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
K. S. ROWIN, H. B. TANOWITZ, and M. WITTNER
Therapy of Experimental Babesiosis
Ann Intern Med, October 1, 1982; 97(4): 556 - 558.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
M. WITTNER, K. S. ROWIN, H. B. TANOWITZ, J. F. HOBBS, S. SALTZMAN, B. WENZ, R. HIRSCH, E. CHISHOLM, and G. R. HEALY
Successful Chemotherapy of Transfusion Babesiosis
Ann Intern Med, May 1, 1982; 96(5): 601 - 604.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1974 by the American Society of Tropical Medicine and Hygiene.